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CT-P13, the biosimilar of inﬂiximab, has been recently approved in the EU, Australia, Canada, Japan and
many other countries. Thus, it was the ﬁrst biosimilar approved in the ﬁeld of rheumatology, derma-
tology and gastroenterology. Since there has been debate about the issue of switching from RMP to the
biosimilar and some national societies have expressed concerns, this review was written with the
following objectives:
- Review the data evaluating the safety and effectiveness of switching to CT-P13 accumulated
thus far from clinical studies and real-world experience.
- Assess the paradigm shift around the use of biosimilar products in terms of recent national
decisions and stakeholder perspectives.
The review concludes that whilst prudent switching practices should be employed, growing safety
experience accumulated thus far with CT-P13 and other biosimilars is favorable and does not raise any
speciﬁc concerns.
© 2016 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Biological agents have revolutionized therapy and transformed
treatment paradigms due to improved short- and long-term clinical
and public health outcomes, and general patient care of chronic and
debilitating autoimmune disorders such as rheumatoid arthritis
(RA), ankylosing spondylitis (AS), psoriasis (Ps) and psoriatic
arthritis (PsA), ulcerative colitis (UC) and Crohn's Disease (CD) as
well as for different forms of cancer and chronic kidney disease.
However, with global spending on medicines approaching to reach
$1.3 trillion by 2018 (IMS, 2014), colossal costs of biological treat-
ments reaching $210 billion by 2016 (IMS, 2012) with relatively low
numbers of patients being treated or assured access globally to
these efﬁcient treatments, long-term expenditure and costs has
become unsustainable for payers and societies. Recent or
impending expiry of patents for some key biologics has led to
development of biosimilar products. With growing numbers ofrin).
Ltd on behalf of International Allian
c-nd/4.0/).biosimilar products there are now more options for healthcare
providers and patients not only to access biological products earlier
but also to possibly switch from costly originator versions to bio-
similar alternatives. The entry of biosimilar products into the
market may well reduce the pressure on healthcare budgets, in-
crease earlier access to biologic therapy, and may facilitate the
efﬁcient allocation of limited ﬁnancial resources [1,2]. Biosimilars
are expected to save 11.8e33.4 billion Euros between 2007 and
2020 in the EU and 44.2 billion US dollars over the 10 year period
between 2014 and 2024 [3,4].
In accordance with regulatory frameworks laid out by the Eu-
ropean Medicines Agency (EMA), the US Food & Drug Adminis-
tration (FDA), the World Health Organization (WHO) and other
authorities in highly regulated jurisdictions, development of bio-
similars has to be accomplished by rigorous and comprehensive
comparability exercises in order to assure similarity of the bio-
similar with the reference medicinal product (RMP) in terms of
quality characteristics, biological activity, safety, efﬁcacy [5]
including the absence of any clinically important differences from
the RMP in terms of safety and effectiveness [6]. The EMA has
pioneered the legal, regulatory and scientiﬁc framework force for Biological Standardization. This is an open access article under the CC BY-NC-
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and 2015, while other assessments of biosimilar products are
ongoing. The WHO enacted biosimilar guidelines in 2009 and its
framework has been put forward into regional and national bio-
similar legislation and allowed to strengthen global regulations of
biosimilars [7].
The Biologics Price Competition and Innovation Act (BPCI Act) in
the US has established an abbreviated approval pathway for bio-
logical products to demonstrate similar efﬁcacy and safety with the
RMP. The federal law has differentiated the approval of products
into two stages: (1) the ‘biosimilar’ has to provide evidence of basic
similarity to the RMP, and (2) an additional approval status called
‘interchangeable biosimilar’ is required to allow for unlimited
transition from the RMP.
As indicated in Public Health Act subsection 351(k) (3), a bio-
similar is considered to be interchangeable with the reference
product if:
 the biological product is biosimilar to the reference product, and
 it can be expected to produce the same clinical result in any
given patient.
In addition, for a biological product that is administered more
than once to an individual, the risk in terms of safety or diminished
efﬁcacy of alternating or switching between use of the biosimilar
and the reference product is not greater than the risk of using the
reference product without such switching or alternating.
Biosimilarity therefore does not imply interchangeability which
is much more stringent. Interchangeability status allows substitu-
tion of RMP with biosimilar without healthcare provider involve-
ment. In addition to interchangeability, there is a concept of
switching between an RMP and its biosimilars. Switching can be
carried out either under consent of healthcare provider or without
such consent but following payer's policy or decision only (auto-
matic substitution) [8].
The approval for interchangeability is rigorous to achieve and
FDA demands to establish safety data clearly showing that no
additional risk is incurred when patients are switched to the bio-
similar as compared to the continuous use of the RMP [9]. Inter-
changeability refers to achievement of same clinical result in any
given patient in terms of quality, safety and efﬁcacy when a bio-
similar is switched or substituted with its respective innovator
biological product, when compared to the use of the reference
product alone. In principle, once the biosimilar product gains
‘interchangeable’ status, it can be automatically substituted for the
prescribed biological product by the pharmacist without consent of
the prescribing physician [9]. However, this provision is subject to
U.S. state laws enforcing substitution legislation. The BPCI Act gives
FDA the authority to designate a biosimilar as interchangeable with
its reference product. This means that the biosimilar may be
substituted for the originator product by the pharmacist without
reference to the prescribing physician. FDA unveiled biosimilar
guidelines in 2012 and in January 2015 approved ﬁrst US-approved
biosimilar, Sandoz's Zarxio™ (ﬁlgrastim-sndz) [10]. However, as of
2015 there are no interchangeable biosimilars approved in the USA.
Despite that the concept of interchangeability has been laid in
BPCIA, the requirements and the data required to accomplish
interchangeable status have not been clearly deﬁned. After long-
term debates no deﬁned path, guidance and clear requirements
were issued in the USA. FDA has yet to clarify the requirements for
interchangeability, although the agency has stated that it highly
recommends that sponsors use a two-step process for obtaining the
interchangeable biologic designation, ﬁrst gaining approval as a
biosimilar and then submitting a supplement with new data to
support interchangeability.Recommendations around interchangeability and substitution
between biosimilar and its RMP are notwithin the remit of EMA but
reside with EU member national authorities [11,12]. Recently some
national agencies in the EU experts issued their position statements
welcoming switching to biosimilar products and raising concerns
over the scientiﬁc purpose, feasibility, utility and usefulness of
over-complex and often unsurmountable interchangeability re-
quirements and how these ﬁt with economically sustainable
placement of these products onto the market [13e19].
Following approval of biosimilars, it is important to decide
whether it is possible to alternate or switch from the originator
product to the biosimilar or vice versa in clinical practice or also to
switch between different biosimilars. However, concepts of inter-
changeability and switcheability have been insufﬁciently studied -
not only in context of biosimilars but also with originator biologics
in general. Switching from one therapy to another one has been an
integral part of medical practice. Indeed, switching can possibly
occur between small molecule drugs, branded and generic syn-
thetic medicines, between synthetic agents in biological agents and
also from one type of biological originator agent (e.g. anti-tumor
necrosis factor (TNF) agent) to a biological product from a
different class (e.g. rituximab). However, switching studies have
never been routinely conducted and sequencing of agents or their
positioning in treatment paradigm was largely based on empirical
evidence or limited clinical trial data. Strategy studies such as
TICORA and BEST have provided some evidence that earlier initia-
tion and more intensive treatment and whenever appropriate
switching to other more potent synthetic disease-modifying anti-
rheumatic drugs (DMARD) resulted in better control of disease
activity in RA patients and improved clinical outcomes at no
additional cost for healthcare [20,21].
Therefore, it is important to recognize that switching may
become necessary for numerous reasons which can be broadly
categorized into the following groups:
 Loss of response of effectiveness of the primary agent;
 Safety concerns including adverse events or immunogenicity;
 Adherence and compliance related factors (e.g. more convenient
route, frequency of administration, palatable oral formulation
etc.);
 Healthcare provider induced switching that can take place in
form of automatic substitution under budgetary or cost-
effectiveness considerations.
 Other considerations that could be prompted by both pharma-
cists and patients, e.g. longer product half-life and stability,
lesser cold-chain requirements, etc.
CT-P13, the biosimilar of inﬂiximab, has been recently approved
in the EU, Australia, Canada, Japan and many other countries. Thus,
it was the ﬁrst biosimilar approved in the ﬁeld of rheumatology,
dermatology and gastroenterology. Since there has been debate
about the issue of switching from RMP to the biosimilar and some
national societies have expressed concerns, we decided to write
this paper with the objectives to review switching experience be-
tween RMPs and their biosimilar versions and principles around
switching to biosimilar products could assure both safe and
economically sustainable use of these products.
2. Original experience with switches between different
biological products
Sequencing of patients with autoimmune diseases through
different lines of immunomodulatory therapies is a cornerstone
approach of clinical practice and is outlined in recommendations of
EULAR, ECCO and other bodies [22e24]. The typical approach is to
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combination non-biologic DMARDs or biologics in non-responders.
The initial biologic used in the vast majority of patients is typically
anti-TNF agent. In clinical trials there is usually a wash-out period
and no randomized controlled studies have been conducted to
assess the safety and effectiveness of switching between biological
products and mostly the original experiences were learned from
various registries and observational studies. These studies yielded
controversial data probably due to various confounding factors and
lack of concurrent free drug concentration and anti-drug formation
monitoring.
The SWITCH study in CD patients evaluated switching stable
patients on inﬂiximab maintenance patients to adalimumab and
found loss of tolerance to adalimumab and high proportion of
discontinuations [25]. Other studies showed that there may be
beneﬁts of switching AS patients between unrelated anti-TNF
agents [26] and also that immunogenicity to inﬂiximab or adali-
mumab may reduce the probability of achieving response in RA or
PsA patients to etanercept or other alternative second anti-TNF
agent [27e32]. Changing the mechanism of action has been ad-
vantageous in comparisons of rituximab and abatacept versus a
subsequent anti-TNF as demonstrated by improvements in RA
disease activity as well as persistence of therapy [33e37]. There is
need to generate more clinical data ideally derived from random-
ized controlled studies or pragmatic studies to determine merits of
switching between originator anti-TNF products. One of such
studies in RA has recently been initiated [38].
3. Biosimilars: evaluation of immunogenicity
Development of biosimilar candidates is reliant on a compre-
hensive and rigorous analytical comparability exercise which is
aimed to establish highly similar structural and functional features.
Over last decade EMA has developed a well-reﬁned biosimilar
pathway and now accumulated experience with approval of 21
products belonging to different classes of recombinant proteins
including two brands of biosimilar inﬂiximab (CT-P13, Remsima®,
Celltrion and Inﬂectra®, Hospira) and more recently biosimilar
etanercept. Global approvals of CT-P13 illustrate that it is possible
to accomplish successful development of a biosimilar monoclonal
antibody despite of the given complexity of analytical, functional
and clinical studies.
In a range of approved indications with reference products there
are often signiﬁcant differences in use of background immuno-
modulatory and/or chemotherapy regimens, the degree of immu-
nocompetence and patient related factors, doses and dosing
schedules. Therefore susceptibility of a different patient population
to product-related toxicity and immunogenicity may vary. Bio-
similar sponsors should provide robust scientiﬁc justiﬁcation for
extrapolation of indications. This justiﬁcation is based on the both
biosimilarity data and the prior data with RMP. There is continu-
ously growing experience with extrapolation of indications with
approved biosimilar products that support the foundation of this
scientiﬁc and regulatory approach [39].
The choice of the patient population for the comparability
indication should take into account the evaluation of immunoge-
nicity accounting for product and patient speciﬁc factors and
concomitant use of immunomodulatory therapies [40,41].
As monotherapy, inﬂiximab and adalimumab are the most
immunogenic of the available anti-TNF MABs, and anti-drug anti-
bodies (ADA) were reported in approximately 50e61% with CD and
RA [42,43]. High-dose tolerance is a well-known immunologic
phenomenon and appears to explain the inverse doseeresponse in
immunogenicity of TNF antagonists, as has been shown for inﬂix-
imab, which was progressively less immunogenic at 1, 3 and 10mg/kg [42]. In addition, concomitant use of methotrexate (MTX) can
reduce the probability of ADA formation [42,44,45]. However some
studies in RA patients treated with 3 mg/kg of inﬂiximab found
anti-inﬂiximab antibodies in >40% of the patients, despite
concomitant MTX treatment [46]. The PLANET-RA study with bio-
similar inﬂiximab CT-P13 has illustrated that up to 50% of patients
concomitantly treated with MTX developed anti-ADA [47,48].
Accordingly, intra-study evaluation of immunogenicity under sin-
gle or multiple-dosing and using appropriately validated methods
is the most adequate approach. Regardless of how sensitive and
compelling pre-licensure immunogenicity data might be, the rarity
of some of some serious events such as pure-red cell aplasia does
not allow adequately capture these in pre-marketing circumstances
and demand well-designed post-marketing registries and obser-
vational studies. Of note in the EU experience with biosimilar
erythropoietins (EPOs) the burden or PRCA events was negligibly
lower compared to the reports with the reference product [49].
Evaluation of the nature of ADA (e.g. neutralizing vs non-
neutralizing) and magnitude of immune response in relation can
assist in understanding of the immunogenicity risk and deter-
mining the clinical relevance of the anti-drug immune response.
Some in vitro studies including disease speciﬁc in vitro experi-
ments or in silico or in vitro predictive immunogenicity models are
very likely to play an increasing role by replacing the need for large
pre-marketing databases and providing with some additional
extrapolation licensure support. Until recently some of these pre-
dictivemethodswere in early stage of validation and had numerous
limitations [50]. However, more recently some of these assays were
reported to predict the immunogenicity risk with some non-
sequence related post-translational modiﬁcations increasing the
breadth of their potential use for in vitro comparative assessment of
immunogenicity. For example, effects of non-sequence derived
post-translational modiﬁcations including those of a biophysical or
biochemical nature such as deimination (or citrullination), deami-
dation, oxidation, dimerization, and protein folding-induced
conformational changes including stress and stability related ag-
gregation that are all widely accepted as determinants of immu-
nogenicity can be now reliably evaluated and predicted using
various in silico and in vitro assays [51].
In vitro cross-immunogenicity study comparing CT-P13 and
inﬂiximab RMP using sera from CD patients who developed anti-
inﬂiximab RMP antibodies has demonstrated high similarity in
binding illustrating similar immunogenicity and presence of the
shared immunodominant epitopes in CT-P13 and inﬂiximab RMP
sequences. In addition, anti-adalimumab antibodies did not cross-
react with CT-P13 or inﬂiximab RMP [52]. Therefore in vitro
studies can be useful in assessment of immunogenicity of bio-
similar products and some of these in vitro studies can be also
tailored to assessment of switch-related immunogenicity risks.
Throughout last two decades an effort in MAB “humanization”
translated in lowering of the incidence of ADA with reference
products and given a rarity of immunogenicity with some products
and its inconsistent relationship with the risk of infusion related
reactions, the emphasis should be on development of both routine
and enhanced post-marketing surveillance of the product and risk
management planning [53]. As we are moving forward from
chimeric products associated with greater immunogenicity risks
into development of biosimilars of more humanized versions of
reference products, and given inherent limitations of clinical
models and much greater ﬁdelity of powerful and extremely sen-
sitive state-of-art analytical techniques, the paradigm of both bio-
similarity and extrapolation should aim to shift into analytical
continuum of comparability and obviate the need for clinical
studies [54]. With strengthened and pro-active pharmacovigilance
systems available in well-developed and regulated markets, the
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comprehensive safety and immunogenicity evaluation across all
indications through pro-active post-marketing surveillance of well
traceable biosimilar products. New pharmacovigilance legislation
instituted by EMA in 2012 has been welcomed since it provided
with focus on performance and effectiveness of risk minimization
activities [53,55]. Instead of routine passive surveillance, post-
approval registries and safety studies are expected from de-
velopers of complex biosimilars and these are aimed to comple-
ment an absence or a shortfall in pre-licensure safety databases
with post-marketing evaluation of rare adverse events or
addressing the missing clinical data in extrapolated indications
[53].
4. A decade of safety experience with biosimilars and
switching in the EU
A substantial and positive effectiveness and safety experience in
the EU has been accomplished with biosimilar products over last
decade through Eudravigilance and from stakeholders and payer
perspectives [39,56,57]. In all cases of approved biosimilars
extrapolation principle has been claimed and employed as justiﬁed
by applicants using a totality of generated biosimilarity dataset and
review of mechanistic and pathophysiological differences between
conditions of use. Satisfactory safety experience of switching be-
tween primary generation of biosimilar ﬁlgrastims and EPOs has
been validated by excellent traceability of adverse events and lack
of any evidence of increase in unwanted safety, immunogenicity or
altered effectiveness of the products under real-world scenario and
tender systems employing these products throughout EU [39,57].
Substantial 10-year safety experience with biosimilar products in
EU translates now into millions patient year exposures. Robust
pharmacovigilance systems and post-marketing registries and
studies are ongoing to further evaluate the safety proﬁle and reﬁne
the understanding around real-world use, although the evidence
from controlled studies is relatively limited [39,57].
Omnitrope® was the ﬁrst EMA-approved recombinant hGH
biosimilar in 2006. Through post-marketing studies and registries
it was found that there is no negative impact on efﬁcacy or unex-
pected adverse events after switching to omnitrope® from its RMP
[58].
Eight biosimilar ﬁlgrastim products were approved by EMA
since 2008. One of them, Zarxio™ was the ﬁrst US approved bio-
similar product. At the time of US approval, the global safety
experience with this product encompassed >7 million patient
years. Post-marketing studies conﬁrmed efﬁcacy and safety of
biosimilar ﬁlgrastim products in the approved indications including
the extrapolated indication of mobilization of stem cells in healthy
donors and did not identify any concerns resulting from switching
[59e62].
Five biosimilar EPOs were approved by the EMA [63,64].
Following approval, randomized, comparative switching studies
have been conducted with these biosimilars in patients with
chronic renal failure [65,66]. These studies demonstrated that there
are highly comparable clinical efﬁcacy and safety proﬁles between
two patients group; switching to a biosimilar EPO or remaining on
originator EPO. Non-randomized analyses also demonstrate that
biosimilar EPOs and originator EPO can be interchanged without
clinically meaningful alterations in efﬁcacy or safety [67,68].
To investigate the differences between originator and biosimilar
EPO utilization, H€orbrand et al. analyzed the database of the
Bavarian statutory health insurance physician's association [69].
This study show that EPO consumption and persistence of patients
on chronic hemodialysis based on deﬁned daily doses is similar
among patients receiving originator, biosimilar, or switchedtherapy (from originator to biosimilar or vice versa). This data
provide with evidence that the persistence on biosimilar product is
not affected following switching.
Recent meta-analysis and systematic review of post-marketing
clinical studies and pharmacovigilance databases provides with
assurance that the switching between EPOs, ﬁlgrastims and growth
hormone biosimilar products do not raise any speciﬁc safety con-
cerns including lack of concerns related to switching [70].
5. Clinical data and switching experience with biosimilar
inﬂiximab CT-P13
Inﬂiximab is a human-murine chimeric monoclonal antibody
against TNF and its biosimilar CT-P13 (Remsima®, Inﬂectra®) was
approved by the EMA in 2013 as a ﬁrst monoclonal antibody bio-
similar. Biosimilarity between CT-P13 and its RMP was demon-
strated by comprehensive physicochemical, non-clinical and
clinical studies including two pivotal clinical studies [48,71,72].
Clinical program PLANET included a therapeutic equivalence
PLANETRA study in 606 patients with RA on background of MTX
that showed equivalent efﬁcacy, comparable PK, immunogenicity
and safety proﬁles of CT-P13 and RMP in RA patients at week 30. In
additional large PK study PLANETAS, PK equivalence and compa-
rable efﬁcacy, immunogenicity and safety of CT-P13 and RMP in 250
AS patients at weeks 30 were demonstrated. AS study was con-
ducted without background immunosuppressive therapies and
illustrated similar immunogenicity proﬁle to that of RMP up to 1
year. Japanese study in 108 Japanese RA patients on background of
MTX demonstrated PK equivalence and comparable efﬁcacy, safety
and immunogenicity of CT-P13 and RMP [72].
Since launch of CT-P13 across EU and other regions post-
marketing safety experience is rapidly growing. As of July 2015,
the post-marketing exposure with CT-P13 for all approved in-
dications across worldwide territories had accumulated to
approximately 24,000 patient-years. There are various post-
marketing registries and studies are ongoing to accumulate safety
experienceswith CT-P13.With regards to switching fromoriginator
inﬂiximab to CT-P13, positive clinical evidence is being accumu-
lated from several observational studies and real-world patient
cohorts.
Extension studies of the PLANETRA and PLANETAS studies were
performed to investigate the longer-term efﬁcacy and safety of
extended CT-P13 treatment over 2 years (maintenance group), and
the efﬁcacy and safety of switching from originator inﬂiximab to
CT-P13 for 1 year (switch group) (Table 1) [73e75].
In RA extension study, 302 patients who participated in 1 year
PLANETRA study entered into the open-label extension phase for an
additional 48 wks: 158 patients were maintained with CT-P13
(maintenance group) and 144 patients were switched from RMP
to CT-P13. At wk 78, ACR20/50/70 response ratewas comparable for
the maintenance group (71.5%/48.3%/24.5%) and switch group
(78.2%/47.9%/29.6%). Through wk 102, ACR20/50/70 response rates
were maintained and were similar in each group; 72.2%/48.3%/
24.5% and 71.8%/51.4%/26.1%, respectively. Good and moderate
EULAR-CRP responses at wks 54, 78 and 102 were observed in
89.4%/79.5%/81.5% of pts in the maintenance group and 87.3%/
85.9%/76.8% of pts in the switch group, respectively. Changes in
DAS28-CRP from baseline were comparable between the two
groups:2.4/2.4/2.4 in themaintenance group;2.4/2.6/2.5
in the switch group, at wks 54, 78 and 102 respectively). EULAR-ESR
response rates and DAS28-ESR results were also comparable be-
tween groups. The proportion of ADA positive patients was com-
parable between the two groups throughout the study and ADA
positivity did not increase signiﬁcantly during year 2 when both
groups were receiving CT-P13: maintenance group, 49.1%, 50.4%
Table 1
Randomized clinical trials and observational studies for switchability of CT-P13.
Country (study) Patient numbers Indication Efﬁcacy Safety Ref
16 countries
(PLANETRA)
302 (maintenance
group ¼ 158, switch
group ¼ 144)
RA Highly similar efﬁcacy between maintenance
and switch groups based on ACR 25/50/70,
DAS28-ESR, DAS28-CRP, EULAR-ESR, and
EULAR-CRP
Comparable
immunogenicity and
treatment-emergent
adverse event proﬁles
[73]
8 countries
(PLANETAS)
174 (maintenance
group ¼ 88, switch
group ¼ 86)
AS Highly similar efﬁcacy between maintenance
and switch groups based on ASAS 20/40, ASAS
partial remission rate, BASDAI, BASFI, BASMI
and chest expansion
Comparable
immunogenicity and
generally comparable
safety proﬁles
[74,75]
South Korea 110 (CD ¼ 59: 32
inﬂiximab-naïve,
27 switch),
(UC ¼ 51: 42 inﬂiximab-
naïve, 9 switched)
IBD Naïve:
- Response: 95.5% and 91.3% in CD and UC
patients, respectively at week 30
- Remission: 77.3% and 47.8% in CD and UC
patients at week 30
AEs related to CT-P13
occurred in 11.8% of UC
patients
[76]
Switch:
Efﬁcacy of CT-P13 was maintained in 92.6% and
66.7% of CD and UC patients, respectively
South Korea 173 (CD ¼ 83: 43
inﬂiximab-naïve,
40 switch),
(FCD ¼ 12: 8 inﬂiximab-
naïve, 4 switch),
(UC ¼ 78: 62 inﬂiximab-
naïve, 16 switch).
IBD Naïve:
- Response: 79.5%, 66.7%, and 72.2% in CD, FCD,
and UC patients, respectively at week 30
- Remission: 59.0%, 50%, and 37% in CD, FCD,
and UC patients at week 30
No unexpected AEs,
well-tolerated
[77]
Switch:
80.6%, 50%, and 45.5% of CD, FCD, and UC
patients, respectively, achieved or maintained
remission
South Korea 17 (CD ¼ 8: 3 inﬂiximab-
naïve, 5 switch,
(UC ¼ 9: 5 inﬂiximab-naïve,
4 switch)
IBD Naïve:
- Response & remission: 87.5% in IBD patients
at week8
One UC patient
experienced arthralgia
[78]
Switch:
- 88.9% showed a similar clinical outcome
compared with originator biologic
Poland 32 (switch) Pediatric CD Switch:
- Response & remission: median PCDAI 48 (at
start of RMP)/8.5 (at switch to CT-P13)/
7.5 (at second CT-P13 infusion)
No unexpected AEs [79]
Finland 39 (switch) RA Switch:
- No statistical signiﬁcant difference in terms of
AUC for pain (VAS), fatigue, PtGlob, PtAct,
HAQ, DrGlob, ESR, CRP at after CT-P13 injec-
tion for 11 months
No immediate safety
signals were observed
[80]
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102, respectively. The frequencies of AEs and SAEs between main-
tenance and switched treatment groups were: 53.5% and 53.8% for
AEs and 7.5% and 9.1% for SAEs, respectively. Infusion-related re-
actions were reported in 10 patients (6.3%) in the maintenance
group and in 4 patients (2.8%) in the switch group. There were no
reports of TB infections in either group. Malignancies were re-
ported in 1 patient (ovarian cancer) in the maintenance group and
in 4 patients (breast cancer, T-cell lymphoma, ovarian cancer and
myeloproliferative disorder) in the switch group [73].
In a smaller AS extension study, a total of 174 patients who
completed PLANETAS entered into the extension phase: 88 were
continuously treated with CT-P13 (maintenance group) and 86
were switched fromRMP to CT-P13 (switch group) for additional 48
weeks. During the extension, ASAS20/ASAS40 rates were similar in
the maintenance group (70.1%/57.5% at wk 78 and 80.7%/63.9% at
wk 102) and the switch group (77.1%/51.8% at wk 78 and 76.9%/
61.5% at wk 102). ASAS partial remission rates were also similar
between groups; 21.8% and 21.7% at wk 78, and 27.7% and 28.2% at
wk 102, respectively. ADA rates were comparable between the two
groups and positivity was maintained throughout the study
(maintenance group, 22.2%, 24.4% and 25.0%; switch group, 26.2%,
31.3% and 30.7%, at wk 54, 78 and 102, respectively). As expected,
ADA negative patients achieved higher ASAS40 responses (main-
tenance group, 62.9%/61.5%/66.1%; switch group, 58.1%/60.0%/71.2%
at wks 54, 78 and 102, respectively) compared with ADA-positivepatients (maintenance group, 38.9%/36.8%/55.0%; switch group,
41.7%/33.3%/45.8% at wks 54, 78 and 102, respectively) with no
differences between the maintenance and switch groups. The
proportion of patients with AEs was 48.9% in the maintenance
compared with 71.4% in the switch group but there was no tem-
poral or exposure related association between occurrence of AEs
and switching. Most of AEs were mild and moderate in terms of
severity. SAEs were reported in 4 patients in each treatment group.
AEs due to hypersensitivity and infusion-related reactions were
similar in both groups (5 patients in the maintenance group vs 2
patients in switch group). There was 1 case of TB in each group and
1 report of prostate cancer in the maintenance group [74,75].
Both RA and AS extension studies did not reveal any signs of
altered efﬁcacy, safety or immunogenicity proﬁle following tran-
sition from RMP to CT-P13. The proportion of immunogenicity
related safety events was similar between maintenance and
switched AS and RA patients.
Up to date, there are ﬁve published observational studies
including the patients switching from originator inﬂiximab to CT-
P13 (Table 1). Clinical efﬁcacy and safety of CT-P13 were evalu-
ated in 110 Korean IBD patients (CD ¼ 59, UC ¼ 51), including 36
patients (CD ¼ 27, UC ¼ 9) switching from originator inﬂiximab to
CT-P13 [74]. Clinical remission, response and safety proﬁle of CT-
P13 were comparable with the historical data of the originator
inﬂiximab in IBD patients. In patients who receive switched treat-
ment from originator inﬂiximab to CT-P13, the efﬁcacy of CT-P13
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respectively. Satisfactory clinical efﬁcacy and safety of CT-P13 were
also conﬁrmed in other observational studies from 173 (CD ¼ 83,
ﬁstulizing CD [FCD] ¼ 12, UC ¼ 78) and 17 (CD ¼ 8, UC ¼ 9) Korean
IBD patients, including 60 (CD ¼ 40, FCD ¼ 4, UC ¼ 16) and 9
(CD¼ 5, UC¼ 4) switching patients, respectively [76,77]. Moreover,
two observational studies including 32 paediatric CD and 39 RA
patients who received switching therapy were also reported in
Europe. In these studies, efﬁcacy and safety were well maintained
after switching [78e80].
Several registries and post-marketing studies are ongoing for
evaluation of CT-P13 in several indications such as RA, AS, CD, UC,
AS, Ps/PsA, and clinical outcomes following switching treatment
from originator inﬂiximab to CT-P13, will be accumulated and re-
ported in these studies (Table 2). In addition, three randomized
clinical trials including about 800 patients are ongoing for evalu-
ating switchability of CT-P13.
With almost complete nationwide uptake of CT-P13 in Norway,
Norwegian authorities have commissioned a clinical trial that is
currently ongoing (NOR-SWITCH; ClinicalTrials.gov identiﬁer
NCT02148640). This is a randomized, double-blind trial to compare
the safety and efﬁcacy of continued originator inﬂiximab treatment
to switching from originator inﬂiximab to CT-P13 in 500 patients
with RA, spondyloarthritis (SpA), UC, CD and Ps. This clinical trial is
carried out by Norwegian regional health trusts and fully funded by
Norwegian government and expected to report results in 2016 [81].
Additional multicenter, randomized, double-blind clinical study
have been initiated to assess safety and non-inferiority of efﬁcacy of
CT-P13 and original inﬂiximab in adults with CD (NCT02096861).
This study is conducted jointly by Celltrion and Hospira/Pﬁzer. In
this study a randomized transition from originator inﬂiximab to CT-
P13 aswell as fromCT-P13 to originator inﬂiximabwill be evaluated.
An extension study in 71 Japanese RA patients evaluated the
safety and efﬁcacy of CT-P13 following a switch from original
inﬂiximab as well as the long-term safety and efﬁcacy of CT-P13.
This study showed consistent safety, immunogenicity and efﬁcacy
proﬁle between maintenance and switch treatment groups [72].
In totality a large amount of clinical data is already available in
patients with different forms of autoimmune diseases who were
switched from RMP to CT-P13 with satisfactory outcomes, sus-
tained efﬁcacy and no sign of increased immunogenicity or any
other safety concerns. Whilst most of this data is derived from
observational cohorts and open-label studies, the role of “real-
world” and pragmatic clinical studies andmethods of collecting the
evidence is increasingly becoming important. It is uncertain
whether large and long-term longitudinal randomized controlled
studies elucidating interchangeability are both feasible and prac-
tical. Therefore it is likely that many biosimilar sponsors will opt for
real-world evidence gathering using observational studies, regis-
tries, databases and surveys.Table 2
Ongoing registries and post marketing studies for evaluation of CT-P13.
Study Country Patients number
NOR-SWITCH study Norway 500
CD switching study 19 countries 214
RA switching study Japan ~100
RA registry in Korea, EU 7 countries 2450
IBD registry in Korea, EU 9 countries
AS registry in Korea, EU 5 countries
Post-marketing study in Korea Korea 1600
BSRBR UK 500
RABBIT Germany 500
RCT: Randomized clinical trial.
BSRBR: The British Society for Rheumatology Biologics Registers.
RABBIT: Rheumatoid Arthritis oBservation of BIologic Therapy.In conclusion, through extension studies evaluating single-way
transition from originator inﬂiximab to CT-P13, initial observa-
tional cohort and studies in RA and IBD patients as well as through
ongoing registries and randomized controlled studies an extensive
safety, effectiveness and immunogenicity experience with switch-
ing to CT-P13 has been accumulated. The clinical data from these
studies, post-marketing pharmacovigilance data and real-world
observational clinical data provide with reassuring safety data in
relation to switching. Thus far no safety or immunogenicity con-
cerns have been raised. Experience with the use of CT-P13 is
continuously growingwith exposure reaching 24,000 patient-years
treated worldwide.6. Changing paradigm in relation to switching
Over last decade a number of learned societies issued their
“position” statements challenging concepts of biosimilarity and
extrapolation but also raising concerns over switching that may
occur in real clinical practice [22,80e82]. A number of surveys
indicate that there are concerns of some stakeholders in relation to
switching due to potentially low educational level amongst pre-
scribers concerning biosimilars [82e85].
Despite of these concerns the uptake of biosimilar products and
the use of biosimilar inﬂiximab are rapidly expanding across the
globe without any risks emerging from switching thus far. A
number of physicians who are passionate about improving patient
access in countries where the very use of biological products was
scarce have experienced switching under their care and are now
actively collecting the data on the use of CT-P13 [86,87]. Under-
standing of safety of product substitution is particularly important
in healthcare systems where under tender agreements the use of
different and potentially multiple products may occur as a result of
pricing competition.
To date, six regulatory authorities of different counties reported
their stance on interchangeability or substitutability of biosimilars
and RMPs, and all these authorities generally have positive views in
relation to substitution (Table 3) [13e19]. Most recent position
statements issued by Medicines Evaluation Board of Netherlands
and Finnish Agency indicated that switching to biosimilars should
be allowed [13,14]. More recently Australian (PBAC) reported that
substitution of biosimilars and RMPs is allowed if the biosimilar is
found to be equivalent in terms of efﬁcacy and safety [17]. Paul-
Ehrlich Institut in Germany has also issued a position statement
regarding interchangeability of biosimilars and stated that decision
on switching “must be based on scientiﬁc data, especially with
regard to proven high-grade comparability of a biosimilar to its
originator product and the scientiﬁc plausibility of all data included
in the discussion” rather being based on arguments “with little
foundation and fears in connection with the exchange of theIndication Study type (ClinicalTrials.gov identiﬁer)
RA, SpA, PsA, UC, CD, and PsO RCT (NCT02148640)
CD RCT (NCT02096861)
RA RCT
RA Registry
IBD (CD,UC) Registry
AS Registry
RA, AS, IBD, PsA, PsO Post-marketing Study
RA Registry
RA Registry
Table 3
Stance of regulatory authorities on interchange and substitution of biosimilars
Regulatory authority Interchange Substitution Ref
EU (EMA) Leaving it to each member country to decide Not permitted at the pharmacy level, and the decision is left to the
prescribing physician
[5,8]
Finland (Fimea) Allowed under supervision of a health care
professional
No comment [13]
Portugal (Infarmed) Allowed under supervision of a health care
professional
No comment [13]
Netherland (MEB) Allowed under supervision of a health care
professional
No comment [14]
France (ANSM) Not recommended Allowed when initiating a course of treatment and only if the prescribing
physician has not marked the prescription as 'non-substitutable’
[15,16]
Australia (PBAC) Allowed Allowed [17]
Italy (AIFA) Allowed under supervision of a health care
professional
Not recommended [18]
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publications” [19].
Jointly these statements reﬂect a paradigm shift in clinical use of
biosimilars. Largely the concerns around switching and re-
quirements for data for interchangeability are based on theoretical
concerns and aversion to risk rather than on solid facts and data.
Professor Kurki has well outlined the science known around bio-
similars [88]. In terms of efﬁcacy, it is unlikely that products con-
taining different versions of the same active substance shown to be
highly similar on analytical, and clinical pharmacology, efﬁcacy,
safety and immunogenicity levels and being comparable at the
population level would act differently in an individual patient.
Theoretically, differences might occur if the formulations of the
biosimilar and the reference product would be very different
causing inter-patient variability. This possibility can be clariﬁed by
reviewing EPARs of the biosimilars available on the EMA website.
Currently, the main concern of switching patients from a
reference product to its biosimilar is immunogenicity. There is no
theoretical basis or clinical evidence suggesting that a switch itself
would cause immunogenicity. The known examples of switch-
related immunogenicity have occurred after a manufacturing pro-
cess change of an innovator product resulting in an inferior version
of the product with altered immunogenicity attributes.
An inferior immunogenicity proﬁle of a biosimilar cannot be
completely ruled out but it is unlikely for several reasons. Firstly,
high similarity in physicochemical characteristics, and presence of
impurities and aggregates provide with assurance of similar
immunogenicity; secondly, the ADA responses with biosimilars are
always thoroughly investigated before the marketing authoriza-
tion. Thirdly, the active substance of a biosimilar has the same
amino acid sequence as the reference product and, thus, shares the
linear T-cell epitopes. A strong immune response would usually
require a new T-cell epitope. Some biosimilar developers now also
conduct in vitro assessment of ELISPOT responses for the compar-
ative immunogenicity purposes. Fourthly, the levels of immuno-
genic impurities and aggregates are tightly controlled at the release
of the biosimilar product. Finally, the knowledge of speciﬁc
immunological risks with innovator product assists biosimilar de-
velopers in developing robust risk management plan and post-
marketing pharmacovigilance activities.
In conclusion, the risks of switching to biosimilar products are
theoretical and not supported by real world safety experience and
extensive use of EU approved biosimilar products for almost 10
years. The science behind development of biosimilars and effective
regulatory policies enacted in the EU provide with sufﬁcient
assurance of safe and effective switching experiences with bio-
similar products. These lessons should be carefully studied and
implemented in other jurisdictions where such experience is still
relatively limited.7. Informed decision by patients and prescribers
In line with recommendation of numerous national authorities,
patients, pharmacists, physicians, nurses and any other pro-
fessionals with prescribing powers should be adequately informed
about their medication and consulted if any changes in their
treatment occur. Patients and prescribers should be able tomake an
informed decision onmerits of switches in terms of their individual
beneﬁt-risk considerations. Switching between products should be
carried out under supervision and monitoring as this is done with
initiation of any biological drug or sequencing of treatment lines.
Whilst cost considerations should not be a prime concern for pre-
scribers and patients, economic conditions and tender environ-
ment in some jurisdictions and countries can substantially vary
inﬂuencing the forecast of treatment access. Patients need to be
adequately informed if their treatment cannot be assured for
appropriate duration of their condition and in such cases patients
should be allowed to make informed and balanced decisions on
how their condition is managed not only short-term but also from
long-term perspective.8. Cost-effectiveness and switching
In recent years there are now numerous concerns raised by
experts over feasibility and adequacy of interchangeability studies
with alternate design recommended by FDA. Not only these studies
are deemed impractical or scientiﬁcally unsound but also with re-
sources, time and effort required for their conduct there might be
delay in access of US patients to affordable biosimilar versions. It is
therefore thought that interchangeability is an unreachable goal
and not so many biosimilar sponsors will opt to conduct complex,
large and long-term switching studies in order to fulﬁll such re-
quirements. Meanwhile, through real-world and pragmatic clinical
studies and experiences, the use of biosimilar products in the ex-US
territories is rapidly expanding.
The beneﬁts of biosimilar use are expected to translate in earlier
access of patients to biological products thus delaying the burden of
disease and delaying disease progression. In addition, cost re-
ductions allow release of funding for other healthcare needs. Cost-
minimization analyses provide with compelling evidence of cost-
effectiveness of biosimilars [89e96].
An important aspect inﬂuencing the attitude of physicians to-
wards biosimilars is reimbursement conditions. Physicians are
likely to offer patients already on biologic therapy a change to a
biosimilar if the patient will beneﬁt from the reimbursement and
cost savings, and if this change results in a continuous medicine
supply [89e91]. Notably, lack of reimbursement strategies was the
main contributor to the slow uptake of biologics in Eastern
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issue has now been largely addressed.
In the last few years, CT-P13 has been introduced into clinical
practice in an increasing number of countries. In Central and
Eastern European (where marketing of CT-P13 began in 2014), the
introduction of CT-P13 has resulted in a 20e60% reduction in the
price of inﬂiximab. Several budget impact analyses have been
conducted to evaluate the cost effectiveness that may be associ-
ated with switching from originator inﬂiximab to CT-P13 in pa-
tients with RA and IBD [89e96]. FromMay 2015 onwards, patients
in Hungary who initiate biologic therapy with inﬂiximab must be
treated with CT-P13. In addition, although a mandatory switch to
CT-P13 in patients currently treated with RMP inﬂiximab is not
recommended, IBD patients in Hungary who relapse more than a
year after the previous biologic therapy was stopped should only
be treated with the biosimilar [91] In Poland, biologic therapy-
naïve patients must be treated with the biosimilar, and patients
receiving RMP are mandated to switch to CT-P13 maintenance
therapy [91]. Furthermore, National Institute for Health and Care
Excellence (NICE) in the UK issued two draft guidances for pa-
tients with AS, axial SpA, and UC which cover the use of bio-
similars [97,98]. Due to the lower price of CT-P13 compared with
RMP, cost savings in the NHS have been projected, depending on
ﬁnal details of the guidance adopted. It is therefore reassuring that
two recently issued guidance recommendations by NICE allowed
the use of biosimilar inﬂiximab ahead of originator versions in
treatment of RA and IBD.
Nevertheless there is still considerable resistance to advent of
biosimilars and switching in a number of countries. Policies and
regulations obstructing entry of biosimilar products may not only
preclude anticipated budget savings and access-related beneﬁts
with biosimilars but also may cause public health harms. Firstly
latter are linked to opportunity costs resulting from delay of access.
Delay or lack of access may cause irreversible end-stage damage or
even loss of life (e.g. with oncology biosimilars). Secondly, under
tender systems in some countries because of the shortage of funds
some healthcare providers are forced to switch patients from bio-
logical agents to suboptimal regimens with synthetic DMARDs or
steroids whilst these patients are unlikely to beneﬁt from those due
to prior failure or lack of tolerance. Finally, the budget savings in
speciﬁc jurisdictions do not provide with savings that on nation-
wide scale can assist healthcare to direct these funds in other ser-
vices and technologies.
Biosimilar development has been set out to accomplish two
main goals: reduce the expenditure of healthcare on costly bio-
logical treatments and improve patient access to these important
and life-changing agents. As we have learned from initially
approved EU biosimilars, economically sustainable biosimilar
market and sizable impact on healthcare savings can be only
accomplished under the following circumstances:
- High quality biosimilar products will be approved under strin-
gent regulatory pathways such as those employed by EMA and
more recently by US FDA;
- Switching of biosimilars developed through rigorous compara-
bility exercise and approved in well-regulated jurisdictions
should be allowed provided it is carried out carefully and
monitored using robust pharmacovigilance tools.9. Conclusions and recommendations
 Switching between products intended for treatment of auto-
immune and oncology disorders is part of medical practice and
sequential treatment paradigm; Experience with switching and safety of biosimilar products
approved in the EU for almost one decade is reassuring and does
not raise any concerns regarding effectiveness or safety;
 Observational studies, registries, cohorts and real-world expe-
riences evaluating safety and efﬁcacy upon switching to CT-P13
showed that there are no concerns relating to safety or efﬁcacy
in patients with AS, RA and IBD.
 Post-marketing global safety experience with CT-P13 is contin-
uously growing and provides with assurance that switching is
both safe and well tolerated.
 Entry of CT-P13 across Europe already provides cost savings and
further economic beneﬁts are anticipated as uptake of the
product is increasing.
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